JPH06271464A - Arachidonic acid-containing composition for prevention or improvement of alimentary disorder - Google Patents

Abstract

PURPOSE:To provide an arachidonic acid-containing composition for prevention or improvement of alimentary disorders, useful as a food, a medicine, a feed, etc. CONSTITUTION:There is provided an arachidonic acid-containing composition for prevention or improvement of alimentary disorders, containing fats and oils of >=2wt.% arachidonic acid content as the essential component. An economical composition for prevention or improvement of alimentary disorders can be provided by using fats and oils containing high-concentration arachidonic acid.

Description

Detailed Description of the Invention

[0001]

FIELD OF THE INVENTION The present invention relates to foods, pharmaceuticals and animal feeds for preventing or treating digestive system disorders through protection of digestive system mucosa containing fats and oils containing a relatively large amount of arachidonic acid as an essential component. The present invention relates to an arachidonic acid-containing composition useful as the above.

[0002]

2. Description of the Related Art Currently, due to harmful substances such as ethanol,
An increasing number of people have gastric inflammation or liver damage due to damage to the mucous membranes of the stomach and liver. Moreover, for example, the frequency of complications of digestive system ulcer in cirrhosis is high, reaching 5 to 15%. It has been said that the reason for this is that the gastrin metabolism in the liver is lowered, the blood gastrin concentration is increased, and the gastric acid secretion is enhanced.

However, recently, as a physiological action of prostaglandin, a cytoprotective action and a gastric acid secretion inhibitory action have been clarified, and it has been found that prostaglandin comprehensively regulates defense factors. In fact, patients with gastrointestinal ulcer have extremely low levels of prostaglandin, and at present, the method of treatment is to administer prostaglandin directly to the stomach of the patient. However, since prostaglandins have strong side effects, alternatives are required.

Recently, arachidonic acid, which is a biological precursor of prostaglandin, has been receiving attention. Arachidonic acid, in vivo, from linoleic acid, γ-linolenic acid,
It is synthesized via dihomo-γ-linolenic acid, and it is believed that this synthetic arachidonic acid is converted into prostaglandins, which is effective in the prevention and treatment of digestive system disorders.

Therefore, it is considered effective to administer linoleic acid or arachidonic acid for the prevention or treatment of gastrointestinal disorders. For example, in JP-A-59-62522, linoleic acid or arachidonic acid may be administered. It is proposed to be orally administered as a water-soluble composition together with a surfactant and used for the prevention and treatment of digestive system disorders. In this case, the administered linoleic acid and arachidonic acid are taken up by phospholipids in the stomach and duodenal mucosa and converted into prostaglandin, which protects the stomach and duodenal mucosa.

Regardless of the case of using linoleic acid, however, a practical preventive or therapeutic agent for digestive system disorders using arachidonic acid has not been found yet. That is, linoleic acid is contained in a large amount in ordinary oil and fat foods, and it is easily available, and although a desired effect can be expected by ingestion as food, arachidonic acid is contained in a small amount in foods such as fish, meat and eggs. However, it is difficult to obtain a sufficient amount at a low cost for the prevention and treatment of digestive system disorders. Also,
In JP 59-62522, purified arachidonic acid in free fatty acid form is used, but this is not practical because it is expensive.

Furthermore, since the biosynthesis of arachidonic acid from linoleic acid is inhibited by harmful substances such as ethanol, the amount of arachidonic acid in patients with gastrointestinal disorders is lower than that in healthy cases. Therefore, it is necessary to directly administer arachidonic acid instead of linoleic acid.

[0008]

In view of such circumstances, the present inventors have conducted diligent research to obtain a practical preventive or therapeutic agent for digestive system disorders using arachidonic acid. JP-A-63-44891 and JP-A-2-
Oils and fats containing a high concentration of arachidonic acid obtained by the microbiological method as disclosed in No. 86789 and the like are suitable for that purpose, and even a composition containing such oils and fats, due to harmful substances such as ethanol. The amount of prostaglandins in the damaged digestive system was increased, and it was found to be useful for the prevention and treatment of digestive system disorders, and the present invention has been completed.

[0009]

Means for Solving the Problems That is, the present invention provides a composition for preventing or treating a gastrointestinal disorder, which comprises an oil and fat having an arachidonic acid content of 2% by weight or more as an essential component. It is a thing. Here, the digestive system means a body organ in which disorders such as inflammation and ulcer may occur when orally ingesting harmful substances such as ethanol, and specifically, the esophagus, the stomach, Duodenum, small intestine and the like can be mentioned.

Since no arachidonic acid content of 2% by weight is found among naturally occurring fats and oils, in the present invention, the arachidonic acid-containing fats and oils obtained from a microorganism having an arachidonic acid-producing ability can be used. The amount is 2% by weight or more, preferably 10 to 99% by weight, more preferably 2
0 to 99% by weight of fats and oils is added as an essential component. If the amount of arachidonic acid is too small, the compounding effect cannot be expected, so that the content of arachidonic acid in the composition of the present invention is 2% by weight or more, preferably 10% by weight or more based on the entire composition. Blend so that

Such an oil or fat containing a relatively high concentration of arachidonic acid can be obtained by using an arachidonic acid-producing bacterium belonging to the genus Mortierella as a carbon source according to the method disclosed in JP-A-63-44891. Glucose and yeast extract as a nitrogen source are used, preferably, the culture is carried out in the presence of soybean oil, and the arachidonic acid-containing fraction is extracted and concentrated. In addition, JP-A-2-
In accordance with the method disclosed in No. 86789, Entomotra (En
It is also possible to mass-produce arachidonic acid at a high concentration in the cells by culturing filamentous fungi of the genus Tomophthora) in a medium to which organic polybasic acid is added, and to collect them rapidly and at low cost. it can.

The composition of the present invention may be constituted by oils and fats containing such a relatively high concentration of arachidonic acid alone or a mixture thereof, or in addition to such oils and fats containing arachidonic acid, docosahexaenoic acid. (Hereafter, D
HA and eicosapentaenoic acid (hereinafter EPA)
, Γ-linolenic acid, α-linolenic acid, linoleic acid, fats and oils containing these acids, for example, soybean oil, sesame oil, refined fish oil, etc., vitamins such as d-α-tocopherol, oyster meat extract, etc. The amino acid, vinegar, salt, sweetener, seasoning such as spice and the like may be appropriately contained.

In particular, it has been found that by incorporating DHA together with arachidonic acid, the action of arachidonic acid in the body is promoted, and the preventive and therapeutic effects on the digestive system disorders are further improved. Generally, DHA has a desired promoting effect when added in a weight ratio of 0.5 to 7 times with respect to arachidonic acid.

By adding oyster meat extract together with arachidonic acid, both fatty acids and amino acids can be ingested, and further preventive and therapeutic effects on digestive system disorders can be expected. Generally, the oyster meat extract has a weight ratio of 2 to 150 times, preferably 1 to arachidonic acid.
The desired effect can be obtained by adding it at a ratio of 5 to 50 times.

The composition of the present invention is prepared by an ordinary method such as oil, emulsion, soft capsule, hard capsule, tablet, granule, solid, chewable agent, dressing,
It can be in the form of medicine such as confectionery, food, etc., and can be orally ingested by a person in need of prevention or treatment of digestive system disorders. Further, if necessary, it may be in a form for parenteral administration according to a known technique such as solubilization, and for example, an injection may be prepared.

Not only humans but also rats, rats, guinea pigs, monkeys, baboons, and other mammals can be used for the prevention and treatment of digestive system disorders. It can also be a liquid additive.

The composition of the present invention is usually 50 to 2000 mg when the daily oral intake of arachidonic acid is adult.
/ Day, preferably 200 to 500 mg / day. For mammals other than humans, the daily oral intake of arachidonic acid is 1 to 50 mg / kg, preferably 5 to 10 mg / kg.

[0018]

The present invention will be described in more detail with reference to Examples and Experimental Examples, but the present invention is not limited thereto. In addition, "%" in an Example means "weight%."

Example 1 A soft capsule was prepared according to a conventional method according to the following formulation. Ingredients Content Arachidonic acid-containing fats and oils 50.0% (Containing 22% or more arachidonic acid) Eicosapentaenoic acid (EPA) -containing refined fish oil 20.0% (Containing 28% or more EPA and 12% or more DHA) Docosahexaenoic acid Purified fish oil containing (DHA) 29.8% (containing 8% or more EPA and 30% or more DHA) Vitamin E extract 0.2%

Example 2 A dressing was produced according to a conventional method according to the following formulation.

Example 3 First, arachidonic acid powder was prepared according to a conventional method according to the following formulation.

Arachidonic acid-containing fats and oils were dissolved in ethanol as a solvent, and the remaining raw materials were mixed, and this solution was added, mixed and dispersed for adsorption, and then heated and dried to remove the solvent and arachidone. Acid powder was used. Using the arachidonic acid powder thus obtained, a hard capsule was manufactured according to a conventional method according to the following formulation.

Example 4 Using the arachidonic acid powder prepared in Example 3, tablets were manufactured according to a conventional method according to the following formulation.

Experimental Example Animal Experiment 1 (Experimental Method) SD male rats (body weight: about 200 g) 24
The tails were divided into 4 groups of 6 tails, which were distinguished by the presence or absence of administration of ethanol and arachidonic acid, and the following experiments were conducted. Animals of each group were orally administered with a feed comprising the following ingredients in an amount of 20 g / day for 14 days. To the ethanol-administered group, ethanol was added by a tube at an amount of 3 g / kg / day each time on an empty stomach. The administration period of ethanol was 2 weeks before the administration of arachidonic acid, and ethanol was added during the administration of arachidonic acid.

The arachidonic acid non-administered group was fed diet with lard 10% added, and the arachidonic acid administration group was fed lard 7% and arachidonic acid 3%. Two weeks later, the animals were sacrificed, the stomach was taken out, the mucous membrane of the stomach was scraped with a glass piece, and the effect of arachidonic acid administration was quantitatively determined as follows. Lard contains a large amount of saturated fatty acids and does not contain arachidonic acid.

Measurement of total phospholipid concentration in gastric mucosa (μg / mg protein wet amount) and arachidonic acid concentration (weight ratio) in gastric mucosal inositol fraction, which is said to contain a large amount of arachidonic acid (result)

[Table 1]

As shown in Table 1, when ethanol was added and lard alone was added, and when lard alone was added without ethanol added, ethanol was added to the total phospholipid concentration and arachidonic acid concentration. Is falling. However, even if ethanol is given by adding arachidonic acid, the total phospholipid concentration and the arachidonic acid concentration in the gastric mucosa are about the same as when ethanol is not given, which is within the normal range. From this, it can be seen that arachidonic acid has an action of preventing a decrease in the total phospholipid concentration and arachidonic acid concentration in the gastric mucosa due to harmful substances such as ethanol, and thus protecting the gastric mucosa.

Animal experiment 2 (Experimental method) SD male rat (body weight: about 200 g) 24
The tails were divided into 4 groups of 6 tails each, one arachidonic acid non-administration group and three arachidonic acid administration groups (dose 5, 20, 10
0 mg / kg), the following experiment was conducted. Thirty minutes after the administration of arachidonic acid to the arachidonic acid administration group, ethanol was orally administered to all groups in an amount of 10 mg / kg. After 1 hour, the animals were slaughtered and their stomachs removed and 1
It was simply fixed with 0% formalin solution, and the length of the ulcer was measured.

(Result)

[Table 2]

As shown in Table 2, the length of the ulcer is shorter when arachidonic acid is administered than when arachidonic acid is not administered. Moreover, as the dose of arachidonic acid increases, the length of the ulcer decreases significantly. From this, it is understood that arachidonic acid has an action of protecting the gastric mucosa and suppressing the development of ulcer.

[0031]

According to the present invention, since arachidonic acid-containing oils and fats that can be mass-produced inexpensively are used instead of arachidonic acid in the form of free fatty acid, it is practically useful for preventing or treating gastrointestinal disorders. Arachidonic acid-containing compositions are provided. In addition to arachidonic acid-containing fats and oils, DH
Addition of A-containing fats and oils and oyster meat extract promotes the action of arachidonic acid in the body, and improves the preventive and therapeutic effects on digestive system disorders.

Continuation of the front page (51) Int.Cl. ⁵ Identification number Reference number within the agency FI Technical display area A61K 9/20 B 7329-4C 9/48 C 7329-4C F 7329-4C 31/20 ACL 9283-4C // (A61K 31/23 35:56) 7431-4C (A61K 31/20 35:56) 7431-4C

Claims (9)

[Claims] 1. An arachidonic acid-containing composition for preventing or treating digestive system disorders, which comprises an oil and fat having an arachidonic acid content of 2% by weight or more as an essential component. 2. The arachidonic acid content of fats and oils is 10% by weight.
The above is the arachidonic acid-containing composition according to claim 1. 3. The arachidonic acid content of fats and oils is 20% by weight.
The above is the arachidonic acid-containing composition according to claim 2. 4. The arachidonic acid-containing composition according to claim 1, which is used for protecting gastric mucosa or treating damage. 5. The method of claim 1 in the form of a soft capsule.
The arachidonic acid-containing composition described. 6. The arachidonic acid-containing composition according to claim 1, further comprising a fat / oil containing docosahexaenoic acid. 7. The arachidonic acid-containing composition according to claim 6, wherein the docosahexaenoic acid content is 0.5 to 7 times the arachidonic acid content. 8. The arachidonic acid-containing composition according to claim 1, which is in the form of a hard capsule mixed with an oyster meat extract. 9. The arachidonic acid-containing composition according to claim 1, which is in the form of a tablet mixed with an oyster meat extract.